Tenmile

Overview

Tenmile is a health technology investment firm focused on addressing unmet medical needs and supporting the development of a globally significant health science and technology sector in Australia. Backed by an initial capital allocation of $250 million from Tattarang, one of Australia's largest private investment groups, Tenmile invests in early-stage companies across various health technology sectors, including digital health, immunology, oncology, microbial resistance, and the microbiome. The firm operates with the agility and confidence of a dedicated health technology investment business, enabling it to act swiftly and provide ongoing support to its portfolio companies. Tenmile's team comprises experienced investors and specialists committed to building a talented and passionate team, with members located in Perth and Sydney. The firm is also a corporate partner in Women in Leadership Development (WiLD), a program providing Australian women in science, technology, engineering, and maths (STEM) with the qualifications, skills, and networks needed to attain senior leadership and board positions. Tenmile's rapidly growing portfolio includes companies such as Aravax, Carina Biotech, CurveBeam AI, Emyria, Inventia Life Science, LimmaTech Biologics AG, Lumos Diagnostics, Mindset Health, Perx, Proxima Bio, Psylo, Revagenix, Rock Health, SpeeDx, Stamford Pharmaceuticals, Sweetch, Tin Alley Ventures, Verge Genomics, and Yosemite. The firm's investment strategy emphasizes supporting innovative companies that address unmet medical needs and promote health equity, aiming to deliver life-changing products and medical treatments in Australia and globally. Tenmile's approach is characterized by its focus on providing seed and expansion capital to health technology companies with innovative solutions to healthcare needs that fill a gap in existing markets and services. The firm seeks investments in technologies that address unmet medical needs in identified growth areas, with an initial focus on opportunities within digital health, precision medicine, immunology, microbiome, biological resistance, and resilience. Investments must have a pathway to market where they can operate as a sustainable business. Tenmile looks for strong and diverse teams who know their domain and market well, developing technologies that have an unfair competitive advantage, offering a step change as opposed to incremental improvements over existing products and services. The firm's team is driven for success, with members including Dr. Steve Burnell (Managing Director), John Hartman (Director), Aizaz Syed (Investment and Portfolio Manager), Arjun Balaji (Investment Associate), Joey Man (Investment Analyst), Emily Casey (Community and Partnerships Lead), Kelsee Sewell (Business Manager), and Dr. Liz Dallimore (Investment Committee Member). Tenmile is committed to building a talented and passionate team and is actively hiring. The firm also considers Environmental, Social, and Governance (ESG) factors in its investment decisions and encourages its investees to improve their ESG risk management and develop more sustainable business practices.

Investment Focus

• Innovative health technology solutions addressing unmet medical needs
• Strong and diverse founding teams with domain expertise
• Technologies offering a significant competitive advantage
• Sustainable business models with clear pathways to market

Portfolio Companies